Literature DB >> 11044309

Midterm follow-up of patients who underwent removal of a left ventricular assist device after cardiac recovery from end-stage dilated cardiomyopathy.

R Hetzer1, J H Müller, Y G Weng, M Loebe, G Wallukat.   

Abstract

OBJECTIVE: Cardiac recovery in end-stage idiopathic dilated cardiomyopathy recently occurred after temporary support with a left ventricular assist device. We report the case histories of patients who underwent removal of the device more than 4 years ago.
METHODS: Since June 1994, 23 patients with end-stage idiopathic dilated cardiomyopathy who were supported by a left ventricular assist device or biventricular assist device for 1 to 26 months (mean, 6 months) underwent removal of the device after complete or extensive cardiac recovery, as revealed by echocardiography.
RESULTS: Seven patients (group A) had recurrent cardiac failure after 4 to 24 months. Transplantation was performed in 6 patients, and one died while on the waiting list. Three patients died of noncardiac causes within a period of 4 months and 3 days after removal of the assist device. Stable cardiac recovery occurred in 13 patients (group B) for 3 to 49 months (mean, 23 months). At the time of implantation, there were no significant differences between the groups with regard to age, hemodynamics, left ventricular ejection fraction, left ventricular internal diameter in diastole, and autoantibody levels. The increase of ejection fraction and the decrease of left ventricular internal diameter in diastole after 2 months were highly significant. The patients in group A had longer histories of heart failure and first cardiac symptoms and duration of assist when compared with group B. Group B demonstrated a quicker cardiac recovery on the assist device, and thus support was shorter. Also, the degree of recovery at assist device explantation was more complete in group B. The age at the time of device placement was the only influencing factor for duration on the assist device. The probability of recurrence of heart failure was influenced by the duration of heart failure.
CONCLUSIONS: In selected patients with idiopathic dilated cardiomyopathy, lasting recovery can be achieved after unloading with a left ventricular assist device. Lasting cardiac recovery seems to be related to functional normalization and a more rapid recovery during the unloading period.

Entities:  

Mesh:

Year:  2000        PMID: 11044309     DOI: 10.1067/mtc.2000.108931

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  6 in total

1.  A novel system of assessing myocardial recovery during left ventricular support: report of a case.

Authors:  Takaya Hoashi; Goro Matsumiya; Yasushi Sakata; Shigetoyo Kogaki; Yoshiki Sawa
Journal:  Surg Today       Date:  2008-02-01       Impact factor: 2.549

Review 2.  Molecular changes occurring during reverse remodelling following left ventricular assist device support.

Authors:  Emma J Birks; Robert S George
Journal:  J Cardiovasc Transl Res       Date:  2010-09-04       Impact factor: 4.132

Review 3.  [Cardiomyopathies. I: classification of cardiomyopathies--dilated cardiomyopathy].

Authors:  H P Schultheiss; M Noutsias; U Kühl; D Lassner; U Gross; W Poller; M Pauschinger
Journal:  Internist (Berl)       Date:  2005-11       Impact factor: 0.743

Review 4.  LVAD as a Bridge to Remission from Advanced Heart Failure: Current Data and Opportunities for Improvement.

Authors:  Christos P Kyriakopoulos; Chris J Kapelios; Elizabeth L Stauder; Iosif Taleb; Rana Hamouche; Konstantinos Sideris; Antigone G Koliopoulou; Michael J Bonios; Stavros G Drakos
Journal:  J Clin Med       Date:  2022-06-20       Impact factor: 4.964

5.  Remission of chronic, advanced heart failure after left ventricular unloading with an implantable left ventricular assist device.

Authors:  Zumrut T Demirozu; O H Frazier
Journal:  Tex Heart Inst J       Date:  2012

Review 6.  Perioperative pharmacotherapy in patients with left ventricular assist devices.

Authors:  Nicholas C Dang; Yoshifumi Naka
Journal:  Drugs Aging       Date:  2004       Impact factor: 4.271

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.